Market Overview

8 Biggest Price Target Changes For Thursday

  • Credit Suisse increased the price target for Kohl's Corporation (NYSE: KSS) from $64 to $74. Kohl's shares closed at $76.25 on Wednesday.
  • SunTrust Robinson Humphrey raised the price target for Darden Restaurants, Inc. (NYSE: DRI) from $104 to $110. Darden shares closed at $90.91 on Wednesday.
  • RBC Capital lowered the price target on Proteostasis Therapeutics, Inc. (NASDAQ: PTI) from $11 to $5. Proteostasis Therapeutics shares closed at $4.90 on Wednesday.
  • Goldman Sachs cut TrueCar, Inc. (NASDAQ: TRUE) price target from $11 to $9. TrueCar shares closed at $9.87 on Wednesday.
  • JP Morgan lowered Canadian Solar Inc. (NASDAQ: CSIQ) price target from $17 to $15. Canadian Solar shares closed at $12.44 on Wednesday.
  • Credit Suisse boosted the price target for Five Below, Inc. (NASDAQ: FIVE) from $88 to $96. Five Below shares closed at $81.28 on Wednesday.
  • Baird raised Axovant Sciences Ltd. (NASDAQ: AXON) price target from $2 to $5. Axovant Sciences shares closed at $4.55 on Wednesday.
  • BMO Capital increased the price target on UnitedHealth Group Incorporated (NYSE: UNH) from $275 to $285. UnitedHealth shares closed at $248.65 on Wednesday.

Posted-In: Price Target ChangesPrice Target Intraday Update Analyst Ratings


Related Articles (CSIQ + AXON)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

The Power Of Spotify Playlists Could Ward Off Aggressive Labels, Analyst Says In Upgrade

MiMedx Audit Results In Restatement Of 5 Years Of Financials